Jennifer Collet
Family · Orlando, FLNPI 1982084034
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,432 and has fallen 97.3% since, to $65 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$807
- Xeris Pharmaceuticals, Inc.$665
- Lilly USA, LLC$537
- Bayer$493
- Boehringer Ingelheim$437
- Sanofi-aventis U.S. LLC$386
- plus $3K from 24 others
What the payments were for
- Food & beverage$5,93499%
- Education$200%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $807 |
| Xeris Pharmaceuticals, Inc. | 45 | $665 |
| Lilly USA, LLC | 26 | $537 |
| Bayer | 21 | $493 |
| Boehringer Ingelheim | 15 | $437 |
| Sanofi-aventis U.S. LLC | 20 | $386 |
| Abbott | 21 | $346 |
| IBSA Pharma Inc. | 14 | $324 |
| Radius Health, Inc. | 13 | $312 |
| Corcept Therapeutics | 14 | $246 |
| Tandem Diabetes Care, Inc. | 2 | $213 |
| Dexcom, Inc. | 8 | $212 |
| Amneal Pharmaceuticals LLC | 12 | $195 |
| Merck | 6 | $116 |
| AbbVie | 8 | $106 |
| Amgen(2 entities) | 5 | $91 |
| Astellas Pharma US Inc | 3 | $70 |
| Medtronic | 3 | $63 |
| Ascensia Diabetes Care US Inc. | 3 | $61 |
| Mannkind Corporation | 1 | $59 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $47 |
| Novartis | 2 | $34 |
| Tolmar, Inc. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $24 |
| Embecta Corp. | 1 | $20 |
| Vivus LLC | 1 | $18 |
| Alvogen Inc | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Vistapharm, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,013 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $107,336 |
| OzempicSemaglutide | 64 | $105,607 |
| MounjaroTirzepatide | 79 | $94,545 |
| TrulicityDulaglutide | 21 | $37,136 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $27,290 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $27,115 |
| FarxigaDapagliflozin Propanediol | 15 | $23,420 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,824 |
| JanuviaSitagliptin Phosphate | 20 | $15,931 |
| RybelsusSemaglutide | 13 | $15,211 |
| TradjentaLinagliptin | 11 | $9,089 |
| SynthroidLevothyroxine Sodium | 84 | $8,583 |
| Levothyroxine Sodium | 196 | $2,095 |
| UnithroidLevothyroxine Sodium | 30 | $1,539 |
| Pioglitazone Hcl | 50 | $1,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $537 | $132,309111 claims |
| Novo NordiskOzempic, Rybelsus | $807 | $120,81977 claims |
| Boehringer IngelheimJardiance, Tradjenta | $437 | $116,42595 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $386 | $27,29015 claims |
| AstraZenecaFarxiga | $15 | $23,42015 claims |
| MerckJanuvia | $116 | $15,93120 claims |
| AbbVieSynthroid | $106 | $8,58384 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $195 | $3,634226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Orlando
- Donna OrtizOrlando$417K
- Lindsey McCabeOrlando$37K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.